Kimo C. Stine

High Impact

Professor of Pediatric Hematology/Oncology

UAMS

27 h-index 83 pubs 2,469 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Kimo C. Stine's research focuses on the treatment of pediatric solid tumors and hematologic malignancies. His work includes evaluating the efficacy of various chemotherapeutic regimens in children with recurrent or refractory solid tumors, such as studies involving cyclophosphamide and topotecan. He has also investigated intensive therapy approaches for metastatic Ewing tumors in children, examining outcomes with growth factor support.

Dr. Stine's research extends to other pediatric hematologic conditions, including studies on thrombopoietin receptor agonist use in children with immune thrombocytopenia. He has also explored the long-term effects of cancer treatment, such as cardiomyopathy in children with Down Syndrome treated for acute myeloid leukemia. His publications demonstrate a commitment to advancing treatment protocols and understanding disease mechanisms in pediatric oncology and hematology.

With an h-index of 27, 83 total publications, and over 2,400 citations, Dr. Stine is recognized as a highly cited researcher. His collaborative network includes researchers from the National Center for Toxicological Research, with whom he has co-authored multiple publications.

Metrics

h-index: 27
Publications: 83
Citations: 2,469

Selected Publications

Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2026)

Cardiovascular Toxicology DOI OpenAlex
Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2025)

Cardiovascular Toxicology DOI OpenAlex
A Novel Germline TP53 Mutation in a Patient With Li-Fraumeni Syndrome: Resolving a Variant of Uncertain Significance (2021)

Journal of Pediatric Hematology/Oncology 1 citation DOI OpenAlex
A NOVEL GERMLINE TP53 MUTATION IN A PATIENT WITH LI-FRAUMENI SYNDROME - RESOLVING A VARIANT OF UNCERTAIN SIGNIFICANCE (2020)

DOI OpenAlex
Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study (2016)

Pediatric Blood & Cancer 94 citations DOI OpenAlex
Nutlin‐3 treatment spares cisplatin‐induced inhibition of bone healing while maintaining osteosarcoma toxicity (2016)

Journal of Orthopaedic Research® 8 citations DOI OpenAlex
The genomic landscape of juvenile myelomonocytic leukemia (2015)

Nature Genetics 313 citations DOI OpenAlex
von Willebrand Factor Multimers in Pediatric Extracorporeal Membrane Oxygenation Support (2014)

ASAIO Journal 27 citations DOI OpenAlex
Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors (2013)

Haemophilia 6 citations DOI OpenAlex
Cisplatin inhibits bone healing during distraction osteogenesis (2013)

Journal of Orthopaedic Research® 41 citations DOI OpenAlex
C-Reactive Protein and Soluble IL-2Receptor Correlate with High Risk of Clinical Sepsis Among Children with Fever and Neutropenia. (2009)

Blood DOI OpenAlex
Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review (2007)

Haemophilia 33 citations DOI OpenAlex
Use of FEIBA for Invasive or Surgical Procedures in Patients With Severe Hemophilia A or B With Inhibitors (2007)

Journal of Pediatric Hematology/Oncology 19 citations DOI OpenAlex
Treatment of Deep Vein Thrombosis With Enoxaparin in Pediatric Cancer Patients Receiving Chemotherapy (2007)

Clinical and Applied Thrombosis/Hemostasis 15 citations DOI OpenAlex
A patient with hyperuricemia and renal failure:answer (2007)

Pediatric Nephrology 1 citation DOI OpenAlex